Related Experiment Videos
Studies on agents with vasodilator and beta-blocking activities. II
1Research Division, Teikoku Hormone Manufacturing Co., Ltd., Kanagawa, Japan.
Chemical & Pharmaceutical Bulletin
|February 1, 1995
Summary
Researchers synthesized novel phenoxypropanolamines with a hydrazinopyridazinyl group. Compound 20k shows significant hypotensive and beta-blocking effects, making it a potential drug candidate.
Area of Science:
- Medicinal Chemistry
- Pharmacology
Background:
- Phenoxypropanolamines are a class of compounds with known pharmacological activities.
- The hydrazinopyridazinyl moiety is explored for its potential contribution to biological effects.
Purpose of the Study:
- To synthesize and evaluate a series of novel phenoxypropanolamines containing a hydrazinopyridazinyl moiety.
- To assess the hypotensive and beta-blocking activities of these synthesized compounds.
Main Methods:
- Chemical synthesis of phenoxypropanolamine derivatives.
- Intravenous administration of synthesized compounds to anesthetized rats.
- Evaluation of hypotensive and beta-blocking activities.
Main Results:
- Several synthesized compounds demonstrated both hypotensive and beta-blocking activities.
- Compound 20k exhibited potent hypotensive activity comparable to hydralazine.
- Compound 20k displayed beta-blocking activity 2.7 times greater than propranolol.
Conclusions:
- The synthesized phenoxypropanolamines with a hydrazinopyridazinyl moiety possess significant pharmacological properties.
- Compound 20k is a promising candidate for further clinical investigation due to its dual activity profile.